Cortesi, M.; Bravaccini, S.; Ravaioli, S.; Petracci, E.; Angeli, D.; Tumedei, M.M.; Balzi, W.; Pirini, F.; Zanoni, M.; Possanzini, P.;
et al. HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer. Cancers 2024, 16, 3752.
https://doi.org/10.3390/cancers16223752
AMA Style
Cortesi M, Bravaccini S, Ravaioli S, Petracci E, Angeli D, Tumedei MM, Balzi W, Pirini F, Zanoni M, Possanzini P,
et al. HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer. Cancers. 2024; 16(22):3752.
https://doi.org/10.3390/cancers16223752
Chicago/Turabian Style
Cortesi, Michela, Sara Bravaccini, Sara Ravaioli, Elisabetta Petracci, Davide Angeli, Maria Maddalena Tumedei, William Balzi, Francesca Pirini, Michele Zanoni, Paola Possanzini,
and et al. 2024. "HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer" Cancers 16, no. 22: 3752.
https://doi.org/10.3390/cancers16223752
APA Style
Cortesi, M., Bravaccini, S., Ravaioli, S., Petracci, E., Angeli, D., Tumedei, M. M., Balzi, W., Pirini, F., Zanoni, M., Possanzini, P., Rocca, A., Palleschi, M., Ulivi, P., Martinelli, G., & Maltoni, R.
(2024). HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer. Cancers, 16(22), 3752.
https://doi.org/10.3390/cancers16223752
